JP7716473B2 - 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 - Google Patents

抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬

Info

Publication number
JP7716473B2
JP7716473B2 JP2023524891A JP2023524891A JP7716473B2 JP 7716473 B2 JP7716473 B2 JP 7716473B2 JP 2023524891 A JP2023524891 A JP 2023524891A JP 2023524891 A JP2023524891 A JP 2023524891A JP 7716473 B2 JP7716473 B2 JP 7716473B2
Authority
JP
Japan
Prior art keywords
pharmaceutical agent
months
subject
mosunetuzumab
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023524891A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022098628A5 (enExample
JP2023548069A (ja
Inventor
ジーチョン リー，
キャロル エレイン オヘア，
ホン ワン，
ブレンダン クリスチャン ベンダー，
イーラジ ホッセイニ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023548069A publication Critical patent/JP2023548069A/ja
Publication of JPWO2022098628A5 publication Critical patent/JPWO2022098628A5/ja
Priority to JP2025095701A priority Critical patent/JP2025143291A/ja
Application granted granted Critical
Publication of JP7716473B2 publication Critical patent/JP7716473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023524891A 2020-11-04 2021-11-02 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 Active JP7716473B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025095701A JP2025143291A (ja) 2020-11-04 2025-06-09 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063109777P 2020-11-04 2020-11-04
US63/109,777 2020-11-04
US202163188561P 2021-05-14 2021-05-14
US63/188,561 2021-05-14
US202163273566P 2021-10-29 2021-10-29
US63/273,566 2021-10-29
PCT/US2021/057676 WO2022098628A2 (en) 2020-11-04 2021-11-02 Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025095701A Division JP2025143291A (ja) 2020-11-04 2025-06-09 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬

Publications (3)

Publication Number Publication Date
JP2023548069A JP2023548069A (ja) 2023-11-15
JPWO2022098628A5 JPWO2022098628A5 (enExample) 2024-11-13
JP7716473B2 true JP7716473B2 (ja) 2025-07-31

Family

ID=78806675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023524891A Active JP7716473B2 (ja) 2020-11-04 2021-11-02 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
JP2025095701A Pending JP2025143291A (ja) 2020-11-04 2025-06-09 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025095701A Pending JP2025143291A (ja) 2020-11-04 2025-06-09 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬

Country Status (10)

Country Link
US (1) US12492261B2 (enExample)
EP (1) EP4240766A2 (enExample)
JP (2) JP7716473B2 (enExample)
KR (1) KR20230100732A (enExample)
AU (1) AU2021374590A1 (enExample)
CA (1) CA3196076A1 (enExample)
IL (1) IL302400A (enExample)
MX (1) MX2023005130A (enExample)
TW (1) TWI888665B (enExample)
WO (1) WO2022098628A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524149A (ja) 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
US20220380466A1 (en) * 2021-06-01 2022-12-01 Genentech, Inc. Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodies
WO2023250367A1 (en) * 2022-06-22 2023-12-28 Genentech, Inc. Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide
EP4612179A1 (en) * 2022-11-02 2025-09-10 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP2020524991A (ja) 2017-06-12 2020-08-27 ノバルティス アーゲー 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用

Family Cites Families (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5144088A (en) 1991-04-26 1992-09-01 Aristech Chemical Corporation Manufacture of neopentyl glycol (I)
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
HK1041221A1 (zh) 1998-08-11 2002-07-05 Idec药物公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
EP2289543A1 (en) 1998-11-09 2011-03-02 Biogen Idec Inc. Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
PT1242438E (pt) 1999-12-29 2007-02-28 Immunogen Inc Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT CONTAINING ANTIBODY COMPOSITION
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2528434A1 (en) 2003-06-05 2005-01-06 Genentech, Inc. Combination therapy for b cell disorders
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk COMPOSITION OF CONDENSED PROTEINS
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
US8219149B2 (en) 2005-06-29 2012-07-10 Nokia Corporation Mobile communication terminal
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
CA2618542A1 (en) 2005-08-09 2007-02-15 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
WO2009085765A1 (en) 2007-12-21 2009-07-09 Genentech, Inc. Crystallization of anti-cd20 antibodies
AR069979A1 (es) 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
WO2009106096A1 (en) 2008-02-27 2009-09-03 Fresenius Biotech Gmbh Treatment of resistant tumors with trifunctional antibodies
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
PE20120204A1 (es) 2008-11-17 2012-03-03 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
US20110178279A1 (en) 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
WO2010114940A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CA2775159A1 (en) 2009-09-25 2011-03-31 Shanghai National Engineering Research Center Of Antibody Medicine Co., Ltd. Method of acquiring proteins with high affinity by computer aided design
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
EP3228315B1 (en) 2010-11-10 2020-11-25 Amgen Research (Munich) GmbH Prevention of adverse effects caused by cd3 specific binding domains
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
US10208129B2 (en) 2010-12-06 2019-02-19 National Research Council Of Canada Antibodies selective for cells presenting ErbB2 at high density
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
CN103429619B (zh) 2011-03-17 2017-07-28 雷蒙特亚特特拉维夫大学有限公司 双特异性和单特异性、不对称抗体和其制备方法
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
ES2686327T3 (es) 2011-08-23 2018-10-17 Roche Glycart Ag Moléculas de unión a antígeno biespecíficas
EP2578230A1 (en) 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US20130165638A1 (en) 2011-12-27 2013-06-27 Development Center For Biotechnology Light chain-bridged bispecific antibody
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
JP2015523380A (ja) 2012-07-09 2015-08-13 ジェネンテック， インコーポレイテッド 抗ｃｄ７９ｂ抗体を含む免疫複合体
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
KR102332790B1 (ko) 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
EP2769989A1 (en) 2013-02-21 2014-08-27 Universitätsklinikum Freiburg Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor
EP3721902A1 (en) 2013-03-14 2020-10-14 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
TW201501724A (zh) 2013-03-15 2015-01-16 Glaxosmithkline Ip No 2 Ltd 低濃度抗體調配物
EP2986630B1 (en) 2013-04-19 2018-08-15 Covagen AG Novel bispecific binding molecules with antitumoral activity
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
SG11201509595PA (en) 2013-05-28 2015-12-30 Dcb Usa Llc Antibody locker for the inactivation of protein drug
EP3004164A1 (en) 2013-05-28 2016-04-13 Numab AG Novel antibodies
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
AU2014287011A1 (en) 2013-07-12 2016-02-25 Zymeworks Inc. Bispecific CD3 and CD19 antigen binding constructs
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
EP3074424B1 (en) 2013-11-27 2025-02-12 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP6841656B2 (ja) 2013-12-17 2021-03-10 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
US9611325B2 (en) 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
WO2016014942A1 (en) 2014-07-25 2016-01-28 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
CR20170032A (es) 2014-08-04 2017-04-04 Hoffmann La Roche Moleculas biespecíficas de unión a antígeno activadoras de células t
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
SI3262071T1 (sl) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Način uporabe imunokonjugatov proti CD79b
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
AU2015355137A1 (en) 2014-12-02 2017-06-08 Celgene Corporation Combination therapies
JP6802158B2 (ja) 2014-12-05 2020-12-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及び使用方法
US20170363614A1 (en) 2014-12-22 2017-12-21 Enumeral Biomedical Holdings, Inc. Methods For Screening Therapeutic Compounds
CN114478792A (zh) 2015-01-08 2022-05-13 根马布股份公司 针对cd3和cd20的双特异性抗体
US10563194B2 (en) 2015-02-24 2020-02-18 BioAlta, LLC Conditionally active biological proteins
EP3778640A1 (en) 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3795679A1 (en) 2015-05-28 2021-03-24 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
CA2986592A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Anti-her2 antibodies and methods of use
EP3313874B1 (en) 2015-06-26 2021-03-10 University of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
LT3844189T (lt) 2018-08-31 2025-02-25 Regeneron Pharmaceuticals, Inc. Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
CA3196191A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP2020503260A (ja) 2016-11-15 2020-01-30 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
JP2020524991A (ja) 2017-06-12 2020-08-27 ノバルティス アーゲー 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood，2019年，Vol.134, Supplement_1，p.1285，https://doi.org/10.1182/blood-2019-123961
npj Systems Biology and Applications，2020年08月，Vol.6, Article No.28，10.1038/s41540-020-00145-7

Also Published As

Publication number Publication date
CA3196076A1 (en) 2022-05-12
IL302400A (en) 2023-06-01
KR20230100732A (ko) 2023-07-05
EP4240766A2 (en) 2023-09-13
AU2021374590A1 (en) 2023-06-01
JP2025143291A (ja) 2025-10-01
WO2022098628A3 (en) 2022-07-07
WO2022098628A2 (en) 2022-05-12
MX2023005130A (es) 2023-05-25
TW202225191A (zh) 2022-07-01
US20220153858A1 (en) 2022-05-19
US12492261B2 (en) 2025-12-09
TWI888665B (zh) 2025-07-01
JP2023548069A (ja) 2023-11-15

Similar Documents

Publication Publication Date Title
JP7716473B2 (ja) 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
JP7762198B2 (ja) 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与
JP2023153118A (ja) 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
JP2025523020A (ja) 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
US20220380466A1 (en) Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodies
CN117440826A (zh) 用抗cd20/抗cd3双特异性抗体进行治疗的给药
CN116457003A (zh) 抗cd20/抗cd3双特异性抗体的皮下给药
JP2025517650A (ja) 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
JP2025512824A (ja) 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投与
CN116917317A (zh) 用于使用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物的治疗的给药
JP2025523845A (ja) 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241105

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250718

R150 Certificate of patent or registration of utility model

Ref document number: 7716473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150